Little justification for use of Avandia and Actos, Heart editorial argues
This article was originally published in Scrip
Executive Summary
Justification for use of GlaxoSmithKline's Avandia (rosiglitazone) and Takeda's Actos (pioglitazone) is weak to non-existent, two physicians argue in a Heart editorial published online.